ADXN Company Profile and Key Details

ADXN has shown mixed momentum, losing 0.0% over the past week and -7.74% over the past quarter, though year-to-date performance is up 6.61%. Short-term trend indicators are bullishly aligned (SMA20 -8.67%, SMA50 -11.1%, SMA200 -16.01%). The stock’s 14-day RSI is 39.83 (weak momentum), while the ATR of 0.47 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -41.99% below its high and over 7.37% above its low. Average 10-day trading volume of 4.10 thousand shares is in line with the 3-month average of 3.87 thousand, indicating normal recent market interest.

Addex Therapeutics Ltd has 1.23 million shares outstanding. The public float is 92.72 million shares, elevated short interest at 0.64% of float. This equals 6.75 thousand shares. The short ratio is 2.3 days. Institutional investors hold 1.13% of the float. Insiders own 0.0%.

The latest quarter delivered EPS of -$1.33. The next quarter is forecast at $nan. Next year's EPS is expected at $25.10. Addex Therapeutics Ltd earnings surprise history is a consistent trend of beating forecasts. The quarter that ended June 20, 2025, missed forecasts by -68.77%. The prior quarter beat by 13600.0%. Over the last six quarters, Apple has recorded several small beats. These include 2428.57% in September 30, 2024.

Addex Therapeutics Ltd last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.85. This means the shares are trading above this model’s fair value.

Addex Therapeutics Ltd (NASDAQ:ADXN) closed at $7.00 USD, gaining $0.86 (14.01%) from the previous close of $6.14. The stock is currently mid-range between its 52-week high and low $5.41 and $12.05. With a market capitalization of about $4.62 million, Addex Therapeutics Ltd is classified as a micro-cap and shows higher-than-market volatility (beta ~1.86). Key stats such as the average daily volume over the past year has been around 4.08 thousand shares, trading with heavier-than-usual volume. Headquartered in Geneva, None, Addex Therapeutics Ltd operates in the Healthcare sector and the Biotechnology industry. Led by CEO Timothy Mark Dyer, the company employs approximately 2 people and listed since February 12, 2020. Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.

Addex Therapeutics Ltd trades at a P/E ratio of -0.82, slightly below the S&P 500 average, with a price-to-sales ratio of 51.85 and a price-to-book ratio of 0.84 suggesting the stock is closer to book value. The P/FCF stands at -2.23, also above market averages.

Our AI price prediction model suggests that Addex Therapeutics Ltd stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.86%, with price expected at $6.50 by May 07, 2026, within a range of $6.07 to $6.89 3-Month Outlook: Projected fall of -7.17%, reaching $5.70 by July 22, 2026, with a range of $5.46 to $5.95. 1-Year Outlook: Projected gain of 26.71%, with price at $7.78 by April 23, 2027, within a range of $0.00 to $6.20.

Addex Therapeutics Ltd (NASDAQ:ADXN) shares are flat 6.61% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Addex Therapeutics Ltd trading at a premium to the broader market with a P/E of -0.82. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $30.00, suggesting 388.6% upside. Our AI forecast model points to short-term strength (5.86% over two weeks), a medium-term fall (-7.17% over three months), and a longer-term gain (26.71% over one year), with expected trading ranges indicating moderate volatility.